• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    VIVUS Inc. (VVUS)

    1.23 Down 0.01(0.81%) May 27, 4:00PM EDT
    ProfileGet Profile for:
    VIVUS Inc.
    351 East Evelyn Avenue
    Mountain View, CA 94041
    United States - Map
    Phone: 650-934-5200
    Website: http://www.vivus.com

    Index Membership:N/A
    Full Time Employees:82

    Business Summary 

    VIVUS, Inc., a biopharmaceutical company, develops and commercializes therapies to address unmet medical needs in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index of 30 or greater, or 27 or greater in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus or high cholesterol; and STENDRA, an oral phosphodiesterase type 5 inhibitor for the treatment of erectile dysfunction. It is also developing Qsymia, which has completed Phase II studies for the treatment of obstructive sleep apnea and diabetes, as well as for other obesity-related diseases, including nonalcoholic steatohepatitis, nonalcoholic fatty liver disease, hyperlipidemia, and hypertension. The company has development, license and clinical trial, and commercial supply agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of avanafil, a PDE5 inhibitor compound for the oral and local treatment of male and female sexual dysfunction. It also has license and commercialization agreements with Berlin-Chemie AG and Auxilium Pharmaceuticals, Inc. to commercialize and promote SPEDRA; and with Sanofi Winthrop Industrie to commercialize and promote avanafil. VIVUS, Inc. was founded in 1991 and is headquartered in Mountain View, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on VIVUS Inc.

    Corporate Governance 
    VIVUS Inc.’s ISS Governance QuickScore as of May 1, 2016 is 9. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 9; Compensation: 9.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Seth H. Z. Fischer , 60
    Chief Exec. Officer, Chief Commercial Officer and Director
    Mr. Mark K. Oki CPA, 47
    Chief Financial Officer and Chief Accounting Officer
    Mr. John L. Slebir Esq., 51
    Sr. VP of Bus. Devel., Gen. Counsel and Sec.
    Mr. Johann Noor Mohamed , 44
    VP and Corp. Controller
    Dr. Santosh T. Varghese M.D., 46
    VP of Medical & Regulatory Affairs, Pharmacovigilance and QA
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders